Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50865 |
Name | tongue squamous cell carcinoma |
Definition | A head and neck squamous cell carcinoma that is located_in the tongue. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer head and neck cancer head and neck carcinoma head and neck squamous cell carcinoma tongue squamous cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | Ceralasertib + Radiotherapy | tongue squamous cell carcinoma | sensitive | detail... |
ATM I1453fs | Radiotherapy | tongue squamous cell carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02993991 | Phase I | Durvalumab + Mocetinostat | Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity | Withdrawn | CAN | 0 |
NCT03799445 | Phase II | Ipilimumab + Nivolumab | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03829722 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Completed | USA | 0 |
NCT03952585 | Phase II | Nivolumab Cisplatin | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04116047 | Phase III | Cisplatin Cisplatin + Durvalumab | CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC) (CompARE) | Active, not recruiting | IRL | GBR | 0 |